Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin alone or with chemotherapy or venetoclax in pediatric and young adult relapsed/refractory leukemias or solid tumors
NL-OMON52703Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idasanutlin in neuroblastoma, Nonhematologic neoplasms, acute myeloid leukemia (AML) and 1 more (4 arms), sponsored by Roche. Primary endpoints: Objective response rate, Complete remission rate and 5 more. Started Sep 2023; status: completed.
02
Drugs
idasanutlin
03
Conditions
neuroblastomaNonhematologic neoplasmsacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON52703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52703.